TFF Pharmaceuticals, Inc

(NASDAQ:TFFP)

Latest On TFF Pharmaceuticals, Inc (TFFP):

Date/Time Type Description Signal Details
2023-05-12 05:34 ESTNewsTFF Pharmaceuticals GAAP EPS of -$0.19 beats by $0.01N/A
2023-03-08 05:48 ESTNewsTFF Pharmaceuticals reports Q4 resultsN/A
2023-02-08 17:45 ESTNewsTFF Pharma appoints Harlan Weismanas permanent chief executive officerN/A
2023-01-09 12:34 ESTNewsTFF Pharmaceuticals names Zamaneh Mikhak as chief medical officerN/A
2022-11-23 08:22 ESTNewsTFF Pharmaceuticals: From Undefeatable To SpeculativeN/A
2022-11-18 09:21 ESTNewsTFF Pharma slips 22% on $10.68M public offeringN/A
2022-11-17 16:30 ESTNewsTFF Pharmaceuticals tumbles 25% after hours on proposed stock offeringN/A
2022-11-15 14:13 ESTNewsTFF Pharmaceuticals, Inc. (TFFP) Q3 2022 Earnings Call TranscriptN/A
2022-11-14 21:29 ESTNewsTFF Pharmaceuticals GAAP EPS of -$0.29 beats by $0.04, revenue of $0.09MN/A
2022-11-02 12:23 ESTNewsTFF Pharma plunges 39% after updating timeline for Phase 2 data readoutsN/A
2022-09-14 00:04 ESTNewsTFF Pharmaceuticals (TFFP) Investor Presentations - SlideshowN/A
2022-08-30 00:21 ESTNewsTFF Pharma: The Potential Is Still Very Much PresentN/A
2022-08-12 14:03 ESTNewsTFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-11 21:58 ESTNewsTFF Pharmaceuticals GAAP EPS of -$0.34 misses by $0.02, revenue of $28MN/A
2022-08-09 17:16 ESTNewsTFF Pharmaceuticals: Q3 Data Is Pivotal In So Many WaysN/A
2022-05-24 12:20 ESTNewsTFF Pharmaceuticals: A Highly Attractive Basket Of OptionsN/A
2022-05-12 11:26 ESTNewsTFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-11 17:49 ESTNewsTFF Pharmaceuticals GAAP EPS of -$0.33 beats by $0.05, revenue of $0.07M beats by $0.02MN/A
2022-05-10 22:14 ESTNewsTFF Pharmaceuticals Q1 Earnings PreviewN/A
2022-04-19 17:57 ESTNewsTFF Pharma posts early-stage data for Niclosamide Inhalation Powder in COVID-19N/A
2022-03-25 11:43 ESTNewsTFF Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call PresentationN/A
2022-03-25 11:43 ESTNewsTFF Pharmaceuticals GAAP EPS of -$1.25 misses by $0.12, revenue of $0.09M misses by $0.59MN/A
2022-03-25 11:43 ESTNewsTFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-18 10:11 ESTNewsTFF Pharma in pact with U.S. army for needle-free medical countermeasuresN/A
2022-03-01 20:00 ESTNewsTFF Pharmaceuticals, Catalent ink contract for inhalation dry powder manufacturingN/A
2022-02-25 03:23 ESTNewsTFF Pharmaceuticals inhaled niclosamide shows efficacy against OmicronN/A
2021-12-21 15:25 ESTNewsTFF Pharma reports final data from Phase 1b study of inhaled voriconazole powder in asthmaN/A
2021-12-02 12:01 ESTNewsTFF Pharmaceuticals: Upside Catalysts Starting To Show Up Amid Omicron, But TimidlyN/A
2021-12-02 12:01 ESTNewsTFF Pharmaceuticals: Data Desert May Be A Thing Of The Past By 2022N/A
2021-11-23 15:57 ESTNewsWarning: TFFP is at high risk of performing badlyN/A
2021-11-16 14:49 ESTNewsTFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-15 19:28 ESTNewsTFF Pharmaceuticals EPS misses by $0.13, misses on revenueN/A
2021-11-09 02:30 ESTNewsTFF Pharmaceuticals completes dosing in early-stage Voriconazole Inhalation Powder studyN/A
2021-10-28 14:33 ESTNewsTFF Pharmaceuticals gets Health Canada approval for niclosamide COVID-19 human trialsN/A
2021-10-14 13:11 ESTNewsTFF Pharma's dry powder COVID-19 antibody reduces viral load in preclinical studyN/A
2021-09-23 21:20 ESTNewsTFF Pharma reports promising results from inhaled tacrolimus powder trial in lung transplantationN/A
2021-09-22 19:29 ESTNewsTFF Pharmaceuticals (TFFP) Investor Presentation - SlideshowN/A
2021-09-09 19:07 ESTNewsTFF Pharmaceuticals: Cautiously OptimisticN/A
2021-08-13 07:41 ESTNewsTFF Pharmaceuticals EPS beats by $0.11N/A
2021-08-13 07:41 ESTNewsTFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-29 12:32 ESTNewsTFF Pharma gains 5% on positive AUG-3387 in vitro data in COVID-19 Delta variantN/A
2021-07-27 04:43 ESTNewsTFF Pharma's Platform Is Highly Relevant In The Battle Against The PandemicN/A
2021-07-22 17:41 ESTNewsTFF Pharmaceuticals: Looking Attractive At These PricesN/A
2021-07-22 17:38 ESTNewsTFF Pharmaceuticals selects lead monoclonal antibody to treat COVID-19N/A
2021-07-22 17:35 ESTNewsTFF Pharma reports preliminary data from Phase 1 trial of tacrolimus inhalation powderN/A
2021-03-26 22:17 ESTNewsTFF Pharmaceuticals prices 2.86M capital raiseN/A
2021-03-20 10:22 ESTNewsTFF Pharmaceuticals: Not A Matter Of If, But When The Shares Will Run Much HigherN/A
2021-03-13 06:18 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 06:41 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 06:41 ESTAnalyst RatingThe Analyst Target Price has increased from $29.5 to $31.Buy

About TFF Pharmaceuticals, Inc (TFFP):

TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company has a research collaboration with the University of Georgia's Center for Vaccines and Immunology and the University of Texas at Austin to evaluate the immunogenicity of universal influenza vaccines; and cooperative research and development agreement with United States Army Medical Research Institute of Infectious Diseases for use of its thin film freezing technology platform. TFF Pharmaceuticals, Inc. also has a joint development and collaboration agreement with Augmenta Bioworks, Inc. to develop commercial products incorporating Augmenta's human-derived monoclonal antibodies for COVID-19 therapeutics; partnership agreement with GreenLight Biosciences Inc. to evaluate a shelf-stable dry powder formulation of GreenLight's COVID-19 messenger RNA vaccine candidate; and feasibility and material transfer agreement with NeuroRx, Inc. The company was founded in 2018 and is based in Austin, Texas.

TFFP Quotes by TradingView

See Advanced Chart

General

  • Name TFF Pharmaceuticals, Inc
  • Symbol TFFP
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 4
  • Fiscal Year EndDecember
  • IPO Date2019-10-25
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Web URLhttp://www.tffpharma.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 10.41
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.75
  • Next Year EPS Estimate -$0.33
  • Next Quarter EPS Estimate -$0.24
  • Return on Assets -34%
  • Return on Equity -57%
  • Earnings Per Share -$2.00
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 359.36 million
  • Analyst Target Price $31
View More

Share Statistics

  • Shares Outstanding 23.14 million
  • Shares Float 14.33 million
  • % Held by Insiders 2020%
  • % Held by Institutions 24.31%
  • Shares Short 221815
  • Shares Short Prior Month 227552
  • Short Ratio 0.58
  • Short % of Float 1%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • 52 Week High $21.14
  • 52 Week Low $3.44
  • 50 Day Moving Average 16.22
  • 200 Day Moving Average 15.81
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

TFF Pharmaceuticals, Inc (TFFP) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

TFF Pharmaceuticals, Inc (TFFP) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-10$N/A-$0.26-$0.22-18.18%
2020-09-302020-11-05$N/A-$0.24-$0.19-26.32%
2020-06-302020-08-13$N/A-$0.20-$0.226.98%
2020-03-312020-05-14$N/A-$0.20-$0.2416.67%
2019-12-312020-03-26$N/A-$2.00

TFF Pharmaceuticals, Inc (TFFP) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 3.05 million N/A N/A 2.24 million 3.27 million
Income Before Tax -5.9 million N/A N/A -3.8 million -4.66 million
Selling General Administrative 2.86 million N/A N/A 1.62 million 1.44 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -5.92 million N/A N/A -3.85 million -4.71 million
Operating Income -5.92 million N/A N/A -3.85 million -4.71 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A 49630
Net Income From Continuing Operations -5.9 million N/A N/A -3.8 million -4.66 million
Net Income Applicable to Common Shares -5.9 million -5.06 million -3.82 million -3.8 million -28.7 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities 227622 -521953 796208 -168858 242119
Total Cash Flow from Investing Activities -293243 N/A N/A N/A N/A
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A 21.85 million -10167
Change to Operating Activities 28543 268543 222730 312820 -246179
Change in Cash N/A N/A -2.36 million 17.54 million -3.08 million
Total Cash from Operating Activities -4.26 million -3.77 million -2.35 million -4.31 million -3.07 million
Depreciation N/A N/A N/A N/A N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 546120 295356 425844 211434 -229015
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 1.32 million N/A N/A 1.2 million 1.54 million
Total Stockholder Equity 37.34 million N/A N/A 25.39 million 27.64 million
Other Current Liabilities 24315 N/A N/A N/A N/A
Total Assets 38.66 million N/A N/A 26.59 million 29.19 million
Common Stock 22535 22226 18672 18672 18451
Other Current Assets 2.26 million N/A N/A N/A N/A
Retained Earnings -34.28 million -28.38 million -23.33 million -19.51 million -15.71 million
Other Liabilities N/A N/A N/A N/A 1.13 million
Other Assets N/A N/A N/A N/A N/A
Cash 35.3 million N/A N/A 25.73 million 28.09 million
Total Current Liabilities 1.32 million 1.57 million N/A 1.2 million 410638
Other Stockholder Equity -51538 -67663 -39491 -20283 N/A
Property, Plant & Equipment 1.1 million 945365 N/A N/A N/A
Total Current Assets 37.56 million 42.21 million N/A 26.59 million 29.19 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 37.34 million 41.58 million 21.84 million 25.39 million 27.64 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.3 million 1.57 million N/A 1.2 million 410638

TFF Pharmaceuticals, Inc (TFFP) Chart:

TFF Pharmaceuticals, Inc (TFFP) News:

Below you will find a list of latest news for TFF Pharmaceuticals, Inc (TFFP) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

TFF Pharmaceuticals, Inc (TFFP) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-07-192.50.05CALL1 00FALSE00
2024-07-1950CALL0 00FALSE00
2024-07-197.50CALL0 00FALSE00
2024-07-192.50PUT0 00TRUE00
2024-07-1950PUT0 00TRUE00
2024-07-197.50PUT0 00TRUE00

Latest TFFP Trades:

Date Shares Price
Jun 13, 2022 5:49 PM EST100$5.42
Jun 13, 2022 5:53 PM EST100$5.57
Jun 13, 2022 5:53 PM EST39$5.55
Jun 13, 2022 5:54 PM EST100$5.57
Jun 13, 2022 7:52 PM EST100$5.54

TFF Pharmaceuticals, Inc (TFFP) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020013471/0001213900-20-013471-index.htm
2020-09-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1733413/000000000020008587/0000000000-20-008587-index.htm
2020-02-03SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1733413/000119312520022641/0001193125-20-022641-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019021028/0001213900-19-021028-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019021030/0001213900-19-021030-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019021033/0001213900-19-021033-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019021035/0001213900-19-021035-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019021037/0001213900-19-021037-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019021039/0001213900-19-021039-index.htm
2019-10-25424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1733413/000121390019021159/0001213900-19-021159-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019021413/0001213900-19-021413-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019021415/0001213900-19-021415-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019021417/0001213900-19-021417-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019021420/0001213900-19-021420-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019021424/0001213900-19-021424-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019021426/0001213900-19-021426-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019021428/0001213900-19-021428-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019021430/0001213900-19-021430-index.htm
2019-10-304/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019021556/0001213900-19-021556-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019025239/0001213900-19-025239-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019025241/0001213900-19-025241-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019025243/0001213900-19-025243-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019025245/0001213900-19-025245-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019025247/0001213900-19-025247-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019025249/0001213900-19-025249-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019025251/0001213900-19-025251-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019025253/0001213900-19-025253-index.htm
2019-12-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1733413/000121390019025650/0001213900-19-025650-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1733413/000121390019026327/0001213900-19-026327-index.htm
2019-12-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390019026904/0001213900-19-026904-index.htm
2020-01-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1733413/000121390020002287/0001213900-20-002287-index.htm
2020-02-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020002686/0001213900-20-002686-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020004227/0001213900-20-004227-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1733413/000121390020007502/0001213900-20-007502-index.htm
2020-03-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1733413/000121390020007544/0001213900-20-007544-index.htm
2020-04-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020008707/0001213900-20-008707-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020009441/0001213900-20-009441-index.htm
2020-04-2910-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1733413/000121390020010404/0001213900-20-010404-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1733413/000121390020012260/0001213900-20-012260-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1733413/000121390020012264/0001213900-20-012264-index.htm
2020-05-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020013471/0001213900-20-013471-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1733413/000121390020021315/0001213900-20-021315-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1733413/000121390020021860/0001213900-20-021860-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1733413/000121390020021865/0001213900-20-021865-index.htm
2020-08-19DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020022897/0001213900-20-022897-index.htm
2020-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020023889/0001213900-20-023889-index.htm
2020-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020023891/0001213900-20-023891-index.htm
2020-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020023893/0001213900-20-023893-index.htm
2020-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020023895/0001213900-20-023895-index.htm
2020-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020023897/0001213900-20-023897-index.htm
2020-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020023899/0001213900-20-023899-index.htm
2020-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020023901/0001213900-20-023901-index.htm
2020-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020023903/0001213900-20-023903-index.htm
2020-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020023905/0001213900-20-023905-index.htm
2020-08-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020024262/0001213900-20-024262-index.htm
2020-09-09S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1733413/000121390020025714/0001213900-20-025714-index.htm
2020-09-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1733413/000121390020026199/0001213900-20-026199-index.htm
2020-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1733413/000121390020028933/0001213900-20-028933-index.htm
2020-09-293Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020028935/0001213900-20-028935-index.htm
2020-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1733413/000121390020029506/0001213900-20-029506-index.htm
2020-10-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1733413/000121390020030487/0001213900-20-030487-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1733413/000121390020035269/0001213900-20-035269-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1733413/000121390020035277/0001213900-20-035277-index.htm
2020-11-05S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1733413/000121390020035288/0001213900-20-035288-index.htm
2019-10-24EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1733413/999999999519002377/9999999995-19-002377-index.htm
2020-09-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1733413/999999999520002460/9999999995-20-002460-index.htm

TFF Pharmaceuticals, Inc (TFFP) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of TFF Pharmaceuticals, Inc (TFFP). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2020%
Institutional Ownership: 2431%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-10-25KIRK ALLEN COLEMANCFO, Secretary, and TreasurerBuy1,000.005.005,000.001,000.00https://www.sec.gov/Archives/edgar/data/1733413/000121390019021413/0001213900-19-021413-index.htm
2019-10-25Glenn R. MattesPresident and CEOBuy10,000.005.0050,000.0010,000.00https://www.sec.gov/Archives/edgar/data/1733413/000121390019021417/0001213900-19-021417-index.htm
2019-10-25Aaron G.L. FletcherDirectorBuy2,000.005.0010,000.002,000.00https://www.sec.gov/Archives/edgar/data/1733413/000121390019021415/0001213900-19-021415-index.htm
2020-04-02Aaron G.L. FletcherDirectorBuy500.003.751,875.0046,419.00https://www.sec.gov/Archives/edgar/data/1733413/000121390020008707/0001213900-20-008707-index.htm
2019-10-25Harlan F WeismanDirectorBuy5,000.005.0025,000.005,000.00https://www.sec.gov/Archives/edgar/data/1733413/000121390019021426/0001213900-19-021426-index.htm
2019-10-25JAMES BRIAN WINDSORChief Science OfficerBuy5,000.005.0025,000.005,000.00https://www.sec.gov/Archives/edgar/data/1733413/000121390019021428/0001213900-19-021428-index.htm
2019-10-25RANDY H THURMANDirectorBuy5,000.005.0025,000.005,000.00https://www.sec.gov/Archives/edgar/data/1733413/000121390019021424/0001213900-19-021424-index.htm
2019-10-25ROBERT S MILLSDirectorBuy5,000.005.0025,000.005,000.00https://www.sec.gov/Archives/edgar/data/1733413/000121390019021420/0001213900-19-021420-index.htm
2020-04-03Aaron G.L. FletcherDirectorBuy16,748.003.9766,489.5663,167.00https://www.sec.gov/Archives/edgar/data/1733413/000121390020008707/0001213900-20-008707-index.htm
2020-04-06Aaron G.L. FletcherDirectorBuy6,252.004.2426,508.4869,419.00https://www.sec.gov/Archives/edgar/data/1733413/000121390020008707/0001213900-20-008707-index.htm
2020-04-15Aaron G.L. FletcherDirectorBuy5,581.004.7226,342.3275,000.00https://www.sec.gov/Archives/edgar/data/1733413/000121390020009441/0001213900-20-009441-index.htm
2020-05-26Aaron G.L. FletcherDirectorBuy20,000.005.08101,600.0095,000.00https://www.sec.gov/Archives/edgar/data/1733413/000121390020013471/0001213900-20-013471-index.htm